Sawyer Alumnus Named CFO of Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc., a biotechnology company focused on the development of products to treat diseases related to free aldehydes, announced that Sawyer Alumnus Stephen Tulipano, has joined Aldeyra as its Chief Financial Officer. Mr. Tulipano will report directly to Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra.

“We are excited to have Steve join Aldeyra, as he brings to the Company a strong financial background and significant experience in the pharmaceutical industry,” said Dr. Brady. “Given his proven track record of managing a company’s finances during clinical trials, Steve will be a tremendous asset as we advance the clinical development of our lead product candidate, NS2, for the treatment of Sjogren-Larsson Syndrome and acute anterior uveitis. We look forward to working with Steve as we continue to pursue a safe and effective treatment option for diseases related to free aldehydes.”

Tulipano has nearly 27 years of accounting and financial experience, of which 12 years were focused on the pharmaceutical industry. Most recently, he held positions at Three Tulips Inc., an accounting and management advisory services firm. Prior to that, he served as Chief Financial Officer of Javelin Pharmaceuticals.

“Joining the Aldeyra team is a great opportunity to be part of an accomplished management team that is pursuing a novel drug platform to treat both orphan and mass-market diseases,” said Tulipano. “I believe my previous experience in financial accounting within the pharmaceutical industry positions me well in this role and I look forward to contributing to the Company’s growth and long-term success.”

Tulipano holds a B.S. in Business Administration and Accounting from Salem State College and an M.B.A. in Finance from the Sawyer School of Management at Suffolk University. He is also a Certified Public Account.

regions: Boston

About the Author